BCYC
Bicycle Therapeutics Plc - ADR

858
Mkt Cap
$311.68M
Volume
424,405.00
52W High
$21.60
52W Low
$6.10
PE Ratio
-1.72
BCYC Fundamentals
Price
$6.17
Prev Close
$6.25
Open
$6.25
50D MA
$7.52
Beta
0.98
Avg. Volume
294,661.78
EPS (Annual)
-$2.91
P/B
0.70
Rev/Employee
$115,704.40
Loading...
Loading...
News
all
press releases
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bicycle Therapeutics plc - BCYC
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bicycle Therapeutics plc - BCYC INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...
PR Newswire·7h ago
News Placeholder
More News
News Placeholder
Bicycle Therapeutics to Participate in the Jefferies London Healthcare Conference
Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today...
Business Wire·8d ago
News Placeholder
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results
Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today...
Business Wire·21d ago
News Placeholder
Entrada Therapeutics (TRDA) Soars 5.6%: Is Further Upside Left in the Stock?
Entrada Therapeutics (TRDA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks·4mo ago
News Placeholder
Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results
Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today...
Business Wire·9mo ago
News Placeholder
Bicycle Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today...
Business Wire·10mo ago
News Placeholder
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on February 3, 2025, the Compensation Committee of the companys Board of Directors granted to 18 new employees inducement awards...
Business Wire·10mo ago
News Placeholder
Bicycle Therapeutics Announces Updated Topline Zelenectide Pevedotin Data and Highlights 2025 Strategic Priorities and Milestones
Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today...
Business Wire·10mo ago
News Placeholder
Bicycle Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today...
Business Wire·11mo ago
News Placeholder
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on January 2, 2025, the Compensation Committee of the companys Board of Directors granted to 12 new employees inducement awards...
Business Wire·11mo ago

Latest BCYC News

View

Advertisement|Remove ads.

Advertisement|Remove ads.